Anyone who can afford to risk some extra cash should be all over this share as the return potential is massive within next 12 months...
We are talking about 20x plus minimum from current valuation if Neuron is any benchmark...or if their slides showing deal values in renal space is any benchmark....
- Forums
- ASX - By Stock
- DXB
- Ann: FSGS Study, Partnering & Commercialisation Investor Briefing
Ann: FSGS Study, Partnering & Commercialisation Investor Briefing, page-75
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $209.1M |
Open | High | Low | Value | Volume |
38.0¢ | 38.5¢ | 36.5¢ | $579.4K | 1.548M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 91570 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 7922 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 91570 | 0.370 |
10 | 171185 | 0.365 |
13 | 301942 | 0.360 |
3 | 73000 | 0.355 |
9 | 211495 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 7922 | 2 |
0.380 | 72644 | 5 |
0.390 | 17637 | 3 |
0.395 | 142800 | 4 |
0.400 | 277640 | 8 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online